EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.

BMC Cancer · 2022 · PMC9533588 · PMID 36195836

Europe PMC DOI

hedged sentence

0.1140

closest p · 2.3× alpha

0.1140

boldest claim

The sentences

showed a trendp = 0.114not close (p > 0.1)

However, TNBC patients with high EVI1 showed a trend towards increased pCR rates compared to low group (37.7% vs 27.5%, p = 0.114; odds ratio 1.60 (95%CI 0.90–2.85, p = 0.110) and numerically better DFS (HR = 0.77 [95%CI 0.48–1.23], log-rank p = 0.271) and OS (HR = 0.76 [95% 0.44–1.31], log-rank p = 0.314) without reaching statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.